These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9394852)
1. A review of endocrine options for the treatment of advanced breast cancer. Kaufmann M Oncology; 1997; 54 Suppl 2():2-5. PubMed ID: 9394852 [TBL] [Abstract][Full Text] [Related]
2. Update on endocrine therapy for breast cancer. Buzdar AU; Hortobagyi G Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518 [TBL] [Abstract][Full Text] [Related]
4. Proper sequence of endocrine therapies in advanced breast cancer. Rose C Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964 [TBL] [Abstract][Full Text] [Related]
6. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma]. Friedrichs K; Jänicke F Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325 [TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in breast cancer: an update. Lake DE; Hudis C Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567 [TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors in breast cancer: current and evolving roles. Hill J; Moore H Cleve Clin J Med; 2002 Jul; 69(7):561-7. PubMed ID: 12109640 [TBL] [Abstract][Full Text] [Related]
9. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women. Nabholtz JM Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238 [TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy in postmenopausal women with breast cancer. Campos SM; Winer EP Oncology; 2003; 64(4):289-99. PubMed ID: 12759523 [TBL] [Abstract][Full Text] [Related]
11. The role of selective non-steroidal aromatase inhibitors in future treatment strategies. Blamey RW Oncology; 1997; 54 Suppl 2():27-31. PubMed ID: 9394858 [TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633 [TBL] [Abstract][Full Text] [Related]
13. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Dodwell D; Vergote I Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126 [TBL] [Abstract][Full Text] [Related]
14. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. Cianfrocca M; Wolff AC Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157 [TBL] [Abstract][Full Text] [Related]
15. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Tobias JS Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457 [TBL] [Abstract][Full Text] [Related]
16. Emerging role of aromatase inhibitors in the treatment of breast cancer. Harvey HA Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789 [TBL] [Abstract][Full Text] [Related]
17. [Endocrine therapy for breast cancer: past and present]. Zhang Y; Liu Y Zhonghua Yi Shi Za Zhi; 2015 Jan; 45(1):28-32. PubMed ID: 26268256 [TBL] [Abstract][Full Text] [Related]
18. Predicting benefit of endocrine therapy for early breast cancer. Regan MM Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197 [TBL] [Abstract][Full Text] [Related]
19. The influence of endocrine treatments for breast cancer on health-related quality of life. Buijs C; de Vries EG; Mourits MJ; Willemse PH Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425 [TBL] [Abstract][Full Text] [Related]
20. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Cheung KL; Owers R; Robertson JF Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]